US 12,077,594 B2
IL2RG binding molecules and methods of use
Robert Kastelein, Menlo Park, CA (US); Deepti Rokkam, Menlo Park, CA (US); Patrick J. Lupardus, Menlo Park, CA (US); and Sandro Vivona, Menlo Park, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Appl. No. 18/006,525
Filed by Synthekine, Inc., Menlo Park, CA (US)
PCT Filed Aug. 5, 2021, PCT No. PCT/US2021/044602
§ 371(c)(1), (2) Date Jan. 23, 2023,
PCT Pub. No. WO2022/031884, PCT Pub. Date Feb. 10, 2022.
Claims priority of provisional application 63/136,098, filed on Jan. 11, 2021.
Claims priority of provisional application 63/135,884, filed on Jan. 11, 2021.
Claims priority of provisional application 63/136,095, filed on Jan. 11, 2021.
Claims priority of provisional application 63/078,745, filed on Sep. 15, 2020.
Claims priority of provisional application 63/061,562, filed on Aug. 5, 2020.
Prior Publication US 2023/0272089 A1, Aug. 31, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/2866 (2013.01) [A61K 45/06 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01)] 22 Claims
 
1. An IL2Rg binding molecule that specifically binds to the extracellular domain of IL2Rg, wherein the IL2Rg binding molecule comprises a single domain antibody (sdAb), and wherein the sdAb comprises a complementary determining region 1 (CDR1), a CDR2, and a CDR3 as shown in a row of the table below:
 
CDR1 CDR2 CDR3
 
FTFDDSDMG TISSDGSTYYADSVKG DFMIAIQAPGAGC
(SEQ ID NO: 2) (SEQ ID NO: 3) (SEQ ID NO: 4)
 
FSFSSYPMT TIASDGGSTAYAASVEG GYGDGTPA
(SEQ ID NO: 6) (SEQ ID NO: 7) (SEQ ID NO: 8)
 
FTFDDREMN TISSDGSTYYADSVKG DFMIAIQAPGAGC
(SEQ ID NO: 10) (SEQ ID NO: 11) (SEQ ID NO: 12)
 
FTFDDSDMG TISSDGNTYYTDSVKG EPRGYYSNYGGRREC
(SEQ ID NO: 14) (SEQ ID NO: 15) NY
 
 
 (SEQ ID NO: 16)
 
FSFSSYPMT TIASDGGSTAYAASVEG GYGDGTPA
(SEQ ID NO: 18) (SEQ ID NO: 19) (SEQ ID NO: 20)
 
FTFSNAHMS SIYSGGSTWYADSVKG NRLHYYSDDDSL
(SEQ ID NO: 22) (SEQ ID NO: 23) (SEQ ID NO: 24)
 
FTFDDREMN TISSDGSTYYADSVKG DFMIAIQAPGAGC
(SEQ ID NO: 26) (SEQ ID NO: 27) (SEQ ID NO: 28)
 
YTFSSYCMG ALGGGSTYYADSVKG AWVACLEFGGSWYDL
(SEQ ID NO: 30) (SEQ ID NO 31) (SEQ ID NO 32)
 
 
 ARYKH
 
FTFDDSDMG TISSDGSTYYADSVKG EPRGYYSNYGGRREC
(SEQ ID NO 34) (SEQ ID NO 35) NY
 
 
 (SEQ ID NO 36)
 
SIYSSAYIG GIYTRDGSTAYADSVKG GRRTKSYVYIFRPEE
(SEQ ID NO 38) (SEQ ID NO 39) YNY
 
 
 (SEQ ID NO 40)
 
FTFSSAHMS SIYSGGGTFYADSVKG NRLHYYSDDDSL
(SEQ ID NO 42) (SEQ ID NO 43) (SEQ ID NO 44)
 
FTFSNAHMS SIYSGGSTWYADSVKG NRLHYYSDDDSL
(SEQ ID NO 46) (SEQ ID NO 47) (SEQ ID NO 48)
 
FIFDDSDMG TISSDGSTYYADSVKG EPRGYYSNYGGRREC
(SEQ ID NO 50) (SEQ ID NO 51) NY
 
 
 (SEQ ID NO 52)
 
FTADDSDMG TISSDGSTYYADSVKG EPRGYYSNYGGRREC
(SEQ ID NO 54) (SEQ ID NO 55) NY
 
 
 (SEQ ID NO 56)
 
FTFSSAHMS SIYSGGGTFYADSVKG NRLHYYSDDDSL
(SEQ ID NO 58) (SEQ ID NO 59) (SEQ ID NO 60)
 
FTFSNAHMS SIYSGGSTWYADSVKG NRLHYYSDDDSL
(SEQ ID NO 62) (SEQ ID NO 63) (SEQ ID NO 64)
 
FTFSNAHMS SIYSGGSTWYADSVKG NRLHYYSDDDSL
(SEQ ID NO 66) (SEQ ID NO 67) (SEQ ID NO 68
 
FTFSSYPMT TIASDGGSTAYAASVEG GYGDGTPA
(SEQ ID NO 70) (SEQ ID NO 71) (SEQ ID NO 72)
 
FTFDDREMN TISSDGSTYYADSVKG DFMIAIQAPGAGC
(SEQ ID NO 74) (SEQ ID NO 75) (SEQ ID NO 76)
 
FTFDDSDMG TISSDGSTYYADSVKG EPRGYYSNYGGRREC
(SEQ ID NO 78) (SEQ ID NO 79) NY
 
 
 (SEQ ID NO 80)
 
YTSCMG TIYTRGRSIYYADSVKG GGYSWSAGCEFNY
(SEQ ID NO 82) (SEQ ID NO 83) (SEQ ID NO 84)
 
FSFSSYPMT TIASDGGSTAYAASVEG GYGDGTPA
(SEQ ID NO 86) (SEQ ID NO 87) (SEQ ID NO 88)
 
FSFSSYPMT TIASDGGSTAYAASVEG GYGDGTPA
(SEQ ID NO 90) (SEQ ID NO 91) (SEQ ID NO 92).